Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Pharmacy, Mount Sinai Hospital, Toronto, Ontario, Canada.
Pharmacotherapy. 2022 Jan;42(1):58-70. doi: 10.1002/phar.2649. Epub 2021 Dec 15.
Pregnant and postpartum individuals are known to have an elevated risk of severe COVID-19 compared with their non-pregnant counterparts. Vaccination is the most important intervention to protect these populations from COVID-19-related morbidity and mortality. An added benefit of maternal COVID-19 vaccination is transfer of maternal immunity to newborns and infants, for whom a vaccine is not (yet) approved. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific binding and neutralizing antibodies are present in infant cord blood and breast milk following natural maternal infection and transfer of maternal immunity following COVID-19 vaccination is an area of active research. In this review, we synthesize the available research, discuss knowledge gaps, and outline factors that should be evaluated and reported when studying the transfer of maternal immunity following COVID-19 vaccination. The data reviewed herein suggest that maternal SARS-CoV-2-specific binding antibodies are efficiently transferred via the placenta and breast milk following maternal mRNA COVID-19 vaccination. Moreover, antibodies retain strong neutralizing capacity. Antibody concentrations appear to be at least as high in infant cord blood as in the maternal serum, but lower in breast milk. Breast milk IgA rises rapidly following maternal vaccination, whereas IgG rises later but may persist longer. At least two COVID-19 vaccine doses appear to be required to reach maximal antibody concentrations in cord blood and breast milk. There is no indication that infants consuming breast milk from vaccinated mothers experience serious adverse effects, although follow-up is limited. No clear pattern has emerged regarding changes in milk supply following maternal vaccination. The heterogeneity in important methodological aspects of reviewed studies underscores the need to establish standard best practices related to research on the transfer of maternal COVID-19 vaccine-induced immunity.
与非孕妇相比,孕妇和产后个体已知患有严重 COVID-19 的风险增加。接种疫苗是保护这些人群免受 COVID-19 相关发病率和死亡率的最重要干预措施。母亲 COVID-19 疫苗接种的另一个好处是将母体免疫力转移给新生儿和婴儿,而这些婴儿尚未批准接种疫苗。在自然母体感染和 COVID-19 疫苗接种后转移母体免疫后,婴儿脐带血和母乳中存在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)特异性结合和中和抗体,这是一个正在积极研究的领域。在这篇综述中,我们综合了现有研究,讨论了知识空白,并概述了在研究 COVID-19 疫苗接种后母体免疫转移时应评估和报告的因素。本文综述的数据表明,在母亲接受 mRNA COVID-19 疫苗接种后,SARS-CoV-2 特异性结合抗体可通过胎盘和母乳有效地转移。此外,抗体保留了强大的中和能力。抗体浓度在婴儿脐带血中的浓度似乎至少与母体血清中的浓度一样高,但在母乳中的浓度较低。母亲接种疫苗后,母乳中的 IgA 迅速上升,而 IgG 上升较晚但可能持续时间更长。至少需要两剂 COVID-19 疫苗才能使脐带血和母乳中的抗体浓度达到最高。没有迹象表明从接种疫苗的母亲那里吸食母乳的婴儿会出现严重的不良反应,尽管随访时间有限。母亲接种疫苗后,牛奶供应没有明显变化。综述研究中重要方法学方面的异质性突显了需要建立与研究母体 COVID-19 疫苗诱导免疫转移相关的标准最佳实践的必要性。